PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Stock Information for PMV Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.